Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Spyre Therapeutics (SYRE) Preferred Shares Issued (2023 - 2024)

Spyre Therapeutics (SYRE) has disclosed Preferred Shares Issued for 3 consecutive years, with -$169.2 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Preferred Shares Issued fell 180.57% year-over-year to -$169.2 million, compared with a TTM value of $197.4 million through Sep 2024, changed N/A, and an annual FY2023 reading of $197.4 million, changed N/A over the prior year.
  • Preferred Shares Issued was -$169.2 million for Q2 2024 at Spyre Therapeutics, down from $169.2 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $210.0 million in Q2 2023 and bottomed at -$210.0 million in Q3 2023.